Dr. Harriet Kluger, MD
Claim this profileYale Cancer Center
Studies Renal Cell Carcinoma
Studies Kidney Cancer
6 reported clinical trials
9 drugs studied
Area of expertise
1Renal Cell Carcinoma
Stage IV
Stage III
ALK positive
2Kidney Cancer
Stage IV
Stage III
ALK positive
Affiliated Hospitals
Clinical Trials Harriet Kluger, MD is currently running
ST-067-001
for Solid Tumors
This trial is testing a new drug called ST-067 on patients with certain types of cancer that have not responded to previous treatments. The goal is to find the safest and most effective dose and to see how well it works against these cancers.
Recruiting1 award Phase 1 & 22 criteria
Etrasimod + Corticosteroids
for Colitis
This is a randomized, double-blind, placebo-controlled, two-arm phase 2 study of etrasimod plus corticosteroids versus placebo plus corticosteroids for the treatment of IMDC CTCAE v5.0 grade ≥ 2 due to ICI therapy alone (α-PD-(L)1 monotherapy or combined with another ICI, such as α-CTLA-4 or α-LAG-3) or ICI plus an oral tyrosine kinase inhibitor that in the opinion of the treating physician requires treatment with corticosteroid-based immunosuppression and does not require immediate secondary immune suppression, such as vedolizumab or infliximab (or equivalent). IMDC is one of the most common Immune Related Adverse Events (irAEs) from treatment with ICI. Current guidelines recommend steroid treatment for IMDC CTCAE grade ≥ 2, which requires temporary or permanent cessation of ICI therapy. Corticosteroids may interfere with the anti-tumor activity of ICIs and are therefore not co-administered. Strategies are needed to both reduce the dose and duration of corticosteroids needed for IMDC treatment and minimize the duration off ICI therapy before re-administering ICI (for those patients in whom it is deemed safe to rechallenge).
Recruiting0 awards Phase 25 criteria
More about Harriet Kluger, MD
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Harriet Kluger, MD has experience with
- APX005M
- Nivolumab
- Ipilimumab
- Etrasimod
- ST-067
- Cabiralizumab
Breakdown of trials Harriet Kluger, MD has run
Renal Cell Carcinoma
Kidney Cancer
Skin Cancer
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Harriet Kluger, MD specialize in?
Harriet Kluger, MD focuses on Renal Cell Carcinoma and Kidney Cancer. In particular, much of their work with Renal Cell Carcinoma has involved Stage IV patients, or patients who are Stage III.
Is Harriet Kluger, MD currently recruiting for clinical trials?
Yes, Harriet Kluger, MD is currently recruiting for 2 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Harriet Kluger, MD has studied deeply?
Yes, Harriet Kluger, MD has studied treatments such as APX005M, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Harriet Kluger, MD?
Apply for one of the trials that Harriet Kluger, MD is conducting.
What is the office address of Harriet Kluger, MD?
The office of Harriet Kluger, MD is located at: Yale Cancer Center, New Haven, Connecticut 06519 United States. This is the address for their practice at the Yale Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.